ArticlePloS one2026
Yttrium-90 radioembolization for neuroendocrine liver metastases: baseline vascularity predicts cytoreduction efficacy.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis retrospective study in patients with neuroendocrine liver metastases analyzes baseline vascularity on MR as a predictor of tumour debulking after conventional Yttrium-90 transarterial radioembolization (TARE).
methods30 patients who underwent TARE at our center between 2015 and 2022 were retrospectively assessed. Pre- and post-treatment target lesion volumes were measured as total tumor volume (TTV) and enhancing tumor volume (ETV). Cox-regression analyses as well as Kaplan-Meier statistics were used to evaluate baseline volumetric imaging parameters and clinical variables as predictors of survival.
resultsMean patients' age was 63 (SD 11) years, 15 were female (50%). The primary tumor was in the upper gastrointestinal tract in 13/30 cases (43%). Median overall survival (mOS) was 33.0 months (95%CI [21.2; 44.7]). Eligibility for peptide receptor radionuclide therapy (PRRT) was the single strongest predictor of survival with a hazard ratio of 0.22 (p = 0.024) and a mOS of 60.8 months whereas receptor-negative patients had the shortest survival of 7.0 months (p = 0.019). A baseline ETV/TTV ratio greater 50% was associated with a decrease in median ETV by 41% after lobar TARE compared to an increase by 18% in patients with poor baseline vascularity (p = 0.018). In the 17/30 patient who received systemic therapies exclusively before TARE, mOS was 15 vs. 6.8 months (p = 0.082). Prior PRRT did not significantly impact the change of ETV after TARE.
conclusionIn lobar TARE for neuroendocrine liver metastases, high baseline vascularity shows an exploratory association with a significant reduction in viable tumor volume, warranting further investigation to improve patient selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.